MYC and plasma cell myeloma: Transcriptional downregulation of MYC might account for the resistance of melanoma cells toward BET bromodomain inhibition by the small molecule JQ1, which has been shown to downregulate MYC transcription and to disrupt the MYC-dependent transcriptional program in multiple myeloma, resulting in potent antiproliferative effects as opposed to the melanoma models examined in this study (Supplementary Figure 8f) [48].